Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wasserman

Showing results (171-180 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Intellectual and academic achievement status after CNS relapse: a retrospective analysis of 40 children treated for acute lymphoblastic leukemiaR K Mulhern, J Ochs, D Fairclough, et al.
Journal of Clinical Immunology|July 18, 2017
Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Blood|August 1, 1987
Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin speciesM Bar-Ner, A Eldor, L Wasserman, et al.
Journal of Clinical Immunology|March 20, 2017
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex<sup>®</sup> 10% Versus Gammaplex<sup>®</sup> 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Radiology Case Reports|April 26, 2021
MR diagnosed chronic exertional compartment syndrome successfully treated by endoscopically-assisted fasciotomyPaul L Wasserman, Matthew Montanarella, David Szames, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
The Journal of Clinical Investigation|May 1, 1988
Complete protein sequences of the variable regions of the cloned heavy and light chains of a human anti-cytomegalovirus antibody reveal a striking similarity to human monoclonal rheumatoid factors of the Wa idiotypic familyM M Newkirk, H Gram, G F Heinrich, et al.
International Journal of Clinical Practice|September 20, 2006
Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfactionK Sheth, R L Wasserman, W R Lincourt, et al.
Drug Safety|July 9, 2024
A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score CalculatorRachel L Wasserman, Diane L Seger, Mary G Amato, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Pageof 26

Showing results (171-180 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Intellectual and academic achievement status after CNS relapse: a retrospective analysis of 40 children treated for acute lymphoblastic leukemiaR K Mulhern, J Ochs, D Fairclough, et al.
Journal of Clinical Immunology|July 18, 2017
Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Blood|August 1, 1987
Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin speciesM Bar-Ner, A Eldor, L Wasserman, et al.
Journal of Clinical Immunology|March 20, 2017
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex<sup>®</sup> 10% Versus Gammaplex<sup>®</sup> 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Radiology Case Reports|April 26, 2021
MR diagnosed chronic exertional compartment syndrome successfully treated by endoscopically-assisted fasciotomyPaul L Wasserman, Matthew Montanarella, David Szames, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
The Journal of Clinical Investigation|May 1, 1988
Complete protein sequences of the variable regions of the cloned heavy and light chains of a human anti-cytomegalovirus antibody reveal a striking similarity to human monoclonal rheumatoid factors of the Wa idiotypic familyM M Newkirk, H Gram, G F Heinrich, et al.
International Journal of Clinical Practice|September 20, 2006
Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfactionK Sheth, R L Wasserman, W R Lincourt, et al.
Drug Safety|July 9, 2024
A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score CalculatorRachel L Wasserman, Diane L Seger, Mary G Amato, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Pageof 26